Treatment Components

The BEXXAR therapeutic regimen is completed over 1-2 weeks¹

THE BEXXAR THERAPEUTIC REGIMEN IS ADMINISTERED IN 2 STEPS

Patients must begin thyroid-protection medication starting at least 24 hours prior to
dosimetric dose and continuing until 14 days after therapeutic dose.

Day 0
Dosimetric Step

Days 7-14
Therapeutic Step

450 mg Tositumomab
(1 hr infusion)*

5 mCi Iodine I 131
Tositumomab (35 mg)
(20 minute infusion)

Whole body
scans X 3^†
• Day 0
• Day 2, 3, or 4
• Day 6 or 7

450 mg Tositumomab
(1 hr infusion)*

Patient-specific activity (mCi) of Iodine I 131
Tositumomab (35 mg) to deliver desired cGy total body dose
(20 minute infusion)

* Patients will be premedicated with acetaminophen and diphenhydramine 30 minutes prior to
the Tositumomab infusion of the dosimetric and therapeutic steps.
- The benefit of premedication in preventing infusion-related toxicity has not been evaluated.

^† Scans used for dosimetry and biodistribution evaluation. If biodistribution is altered, the
therapeutic dose should not be administered.

Premedication with acetaminophen and diphenhydramine must be given with the dosimetric and therapeutic steps
- The benefit of premedication in preventing infusion-related toxicity has not
been evaluated
Total body scans are used for dosimetry and evaluation of biodistribution. If biodistribution is altered, the therapeutic step should not be administered
The biodistribution of Iodine I 131 Tositumomab should be assessed by determination of total body residence time and visual examination of whole body camera images from the first image taken at the time of Count 1 (within an hour of the end of the infusion) and from the second image taken at the time of Count 2 (at 2 to 4 days after administration). An evaluation of the third image at the time of Count 3 (6 to 7 days after administration) is necessary, and may help resolve ambiguities
The BEXXAR therapeutic regimen should be administered only by healthcare professionals qualified by training in the safe use and handling of therapeutic radionuclides and by physicians who are in the process of being or who have been certified by GlaxoSmithKline in dose calculation and administration of BEXXAR

Click here for Important Safety Information about BEXXAR

Click here for Detailed Safety Information

Complete Prescribing Information for
BEXXAR (Tositumomab and Iodine I 131 Tositumomab)

[ RETURN TO TOP ]